Full history for every metric is available with a Kvantra account

Stock profile

Nichi-Iko Pharmaceutical Co., Ltd. (4541.T)

Country: JapanSector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: JPX

Delisted · last close 21 Aug 2024

Current price
32.14 JPY+0.97%
Last close 21 Aug 2024
Benchmarks

Key financial summary

Financials in JPY
201720182019202020212022TTM
Total revenue¥tn0160001721
Operating profit¥tn11
Net profit¥tn010-0-011
EPS reported¥128.0263.3
Operating cashflow per share¥418.4418.4
Capex per share¥93.3593.35
FCF per share¥325.0325.0
Free cash flow¥tn20
Net debt¥tn01
Book value equity¥tn1010
Book value per share¥1,9782,030
Number of sharesm5,088.925,088.92
DPS (TTM paid)¥41.950.00

Financial summary

Financials in JPY
201720182019202020212022TTM
Value
P/E TTMx0.21-
P/B LTMx0.010.00
P/S LTMx0.010.00
P/FCF LTMx0.080.01
EV/EBITDA LTMx0.330.42
EV/Sales LTMx0.040.03
Earnings Yield LTM%476.19%365.73%
FCF Yield%1226.9%17512.1%
Quality
ROE%6.47%12.93%
ROIC%7.89%7.89%
Operating margin%4.62%4.62%
Gross margin%19.70%19.70%
FCF/Sales%9.78%9.78%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%+9342.5%-
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%158.36%0.00%
Dividend Growth%--
Payout Ratio%32.77%15.09%
FCF/Debtx0.380.09
Net Debt/EBITDAx0.270.27
EBIT/Net interestx0.000.00
Net debt/market cap%227.79%23459.6%
Net debt/Equityx0.030.06
Gross debt/equityx0.430.47

Company overview

Nichi-Iko Pharmaceutical Co., Ltd. actively manufactures, distributes, imports, and sells a wide variety of pharmaceutical products. Operating through its Sagent Group and Nichi-Iko Group segments, the company primarily focuses on the development and production of generic drugs. Its extensive product line encompasses antidiabetic, antacid, and antireflux agents, as well as beta-blockers, hypnotics, sedatives, angiotensin II antagonists (including combinations with diuretics), dyslipidemic agents, and calcium antagonists. These offerings target conditions affecting the circulatory, digestive, respiratory, central, and peripheral nervous systems, among others. Beyond pharmaceuticals, the company is also involved in packaging design and exports its products internationally. Established in 1947 as Nihon Iyakuhin Kogyo Co., Ltd., the firm officially became Nichi-Iko Pharmaceutical Co., Ltd. in 2005 and is headquartered in Toyama, Japan.

WebsiteN/A
IndustryDrug Manufacturers - Specialty & Generic
CountryJapan
Trades inJPY

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Delisted · last close 21 Aug 2024

Nichi-Iko Pharmaceutical Co., Ltd. (4541.T)

4541.T · JPX · Healthcare
32.14 JPY+0.97%
Benchmarks
Financialsin JPY
20212022TTM
About

Nichi-Iko Pharmaceutical Co., Ltd. actively manufactures, distributes, imports, and sells a wide variety of pharmaceutical products. Operating through its Sagent Group and Nichi-Iko Group segments, the company primarily focuses on the development and production of generic drugs. Its extensive product line encompasses antidiabetic, antacid, and antireflux agents, as well as beta-blockers, hypnotics, sedatives, angiotensin II antagonists (including combinations with diuretics), dyslipidemic agents, and calcium antagonists. These offerings target conditions affecting the circulatory, digestive, respiratory, central, and peripheral nervous systems, among others. Beyond pharmaceuticals, the company is also involved in packaging design and exports its products internationally. Established in 1947 as Nihon Iyakuhin Kogyo Co., Ltd., the firm officially became Nichi-Iko Pharmaceutical Co., Ltd. in 2005 and is headquartered in Toyama, Japan.

IndustryDrug Manufacturers - Specialty & Generic
CountryJapan
Trades inJPY

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free